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Abstract: A facile synthesis of the C4-substituted isoquinolines 5a-c and 6a-c is described. Commercially available 4-
bromoisoquinoline is converted to the ,-unsaturated esters 8 and 10 on treatment with the appropriate acrylate ester un-
der Heck reaction conditions. The saturated amides 5a-c were obtained from the reaction of ester 9 with the requisite pri-
mary amine. Similarly the unsaturated analogues 6a-c were prepared by reacting ester 10 with the appropriate amine. The 
cytotoxicity of the target molecules was evaluated in two tumour cell lines in vitro. Two compounds, 6b and 6c, showed 
sufficient activity in the human non-small cell lung cancer line NSCLC-N16-L16 to be worthy of further study. 
INTRODUCTION 
  Suitably substituted quinolines and isoquinolines constitute 
the principal subunits of a large number of linear and angular 
aromatic “frameworks” with cytotoxic properties (Langer Clin 
Cancer Res 1999) [1] (von Nussbaum JMC 1999) [2]. These 
molecules interact either with topoisomerase II or bind in the 
major or minor groove of DNA. In some cases they form 
DNA-intercalated molecular complexes, which are stabilized 
via  hydrophobic interactions, hydrogen bonding and/or van 
der Waal’s forces (Morrell JMC 2006) [3]. The presence of 
nitrogen bearing side chain(s) in specific positions of their 
skeletons improves binding affinity and enhances solubility 
under physiological conditions (Werbel JMC 1986) [4]. Previ-
ously, we have published the synthesis of the cytotoxic pyr-
roloquinoline derivatives 1-3 (Fig. 1) (Vlachou Heterocycles 
2002) [5] and their isomeric pyrroloisoquinolines 4a-e (Fig. 1) 
(Vlachou EJPS 2002) [6]. 
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Fig. (1). Structures of derivatives of 1H-pyrrolo[2,3-f]quinoline 1a-
e, 3H-pyrrolo[2,3-f]quinoline 2a-e, 1H-pyrrolo[3,2-h]quinoline 3a-
e and 1H-pyrrolo[2,3-f]isoquinoline 4a-e. 
  In these molecules the spatial orientation of the side 
chain with respect to the planar aromatic chromophore   
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appears to influence their cytotoxic potency and DNA-
binding affinity. Based on these findings we present herein 
the synthesis and biological activity of the C4-substituted 
isoquinolines 5a-c (Scheme 1) and 6a-c (Scheme 2), which 
constitute structurally related congeners of 1-4. For the syn-
thetic plan we had to start with commercially available 4-
bromoisoquinoline (7), which was reacted with ethyl acrylate 
under Heck reaction conditions (Sakamoto Heterocycles 
1981) [7] to give ,-unsaturated ethyl ester 8 in 79% yield 
as a single isomer of trans geometry. Catalytic hydrogena-
tion of 8 over Pd/C in THF under 50 psi pressure led to the 
formation of the saturated ethyl ester 9, which was converted 
to the desired amides 5a-c, upon heating (110
oC) with the 
appropriate primary amine [8]. 
  However, analogous treatment of the unsaturated ester 8 
with the same amines did not lead to the desired compounds 
6a-c in a satisfactory yield. The situation was rectified by 
substituting ethyl acrylate 8  with its methyl congener 10, 
which was prepared from 4-bromoisoquinoline (7) and 
methyl acrylate under Heck conditions (Scheme 2). The new 
4-isoquinoline propanamides 5a-c  and their unsaturated 
counterparts 6a-c were examined for in vitro cytotoxicity in 
a panel of two tumour cell lines (Table 1). In the leukemia 
K562 cell line none of the tested compounds showed any 
noticeable potency. Although most of the compounds tested 
were also inactive in the human non-small lung cancer cell 
line NSCLC-N16-L16 (an IC50 of 10 μM or lower is gener-
ally considered as “active” in anticancer drug discovery), the 
unsaturated analogues 6b and 6c, with IC50 values 44.0 and 
35.6 μM, respectively, are considered as active in this par-
ticular tumour and suitable candidates for further biological 
evaluation. 
  It is noteworthy that few agents, e.g. dactinomycin, are 
clinically effective against human non-small lung cancer, 
and thus there is a need for novel agents for use in this dis-
ease. 
  The fact that the unsaturated piperidino analogue 6c is 
marginally more active in this line than its congener 6b can 
be possibly attributed to the increased basicity of piperidine  
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(pyrrolidine’s pka=11.11; pka of piperidine =11.29 [9]). The 
lack of potency in NSCLC-N16-L16 shown by the saturated 
analogues 5a and 5c is probably due to the different spatial 
orientation of their flexible side chains. Conversely, it seems 
that the “locked” geometry of the side chains of 6b and 6c 
allows them to interact in a more favorable way with the 
backbone of DNA (Tsotinis LDDD 2005) [11] (vide 3D struc-
ture of 6c against 5a, Fig. 2). It is interesting that the spatial 
disposition of the side chain of the weak saturated non-small 
lung cancer growth inhibitor 5b resembles that of 6c is (Fig. 2). 
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Fig. (2). Energetically favoured conformations of 6c, 5b and 5a; the structures were obtained with the aid of HyperChem™ 7.0 Molecular 
Modeling System. 
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Scheme 1. Synthesis of the new saturated amides 5a-c. 
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CONCLUSIONS 
  A short synthetic route to C4-substituted isoquinolines is 
described. Two of the analogues produced, 6b and 6c, have 
cytotoxicity in the NSCLC-N16-L16 cell line and may pro-
vide new leads in the search for effective cytotoxic agents. 
Table 1.  Cytotoxicity of the New Analogues in the K562 and 
NSCLC-N16-L16 Carcinoma Cell Lines 
 
Compound  K562  
(IC50 in μM)
a 
NSCLC-N16-L16  
(IC50 in μM)
b 
5a  > 100  Inactive 
5b  > 100  124.4 ± 7.6 
5c  Inactive Inactive 
6a  > 100  Inactive 
6b  > 100  44.0 ± 1.2  
6c  Inactive  35.6 ± 0.9 
aIC50 values were measured by using a microculture tetrazolium assay (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, MTT) following a 72 h 
exposure to drug at 37
oC. 
bIC50 values were determined by using the MTT assay; three 
concentrations of the drugs were tested in duplicate and cell growth was evaluated at 
72 h (Mosmann J Immunol Methods 1983) [10].  
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